APA (7th ed.) Citation

E, K., D, v. d. H., Jr, M. D., R, L., R, v. V., B, C., . . . K, P. (2008). Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & Rheumatism, 58(11), 3319. https://doi.org/10.1002/art.23964

Chicago Style (17th ed.) Citation

E, Keystone, et al. "Certolizumab Pegol Plus Methotrexate Is Significantly More Effective than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-two-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study." Arthritis & Rheumatism 58, no. 11 (2008): 3319. https://doi.org/10.1002/art.23964.

MLA (9th ed.) Citation

E, Keystone, et al. "Certolizumab Pegol Plus Methotrexate Is Significantly More Effective than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-two-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study." Arthritis & Rheumatism, vol. 58, no. 11, 2008, p. 3319, https://doi.org/10.1002/art.23964.